ArticleOncology letters2020
RRBP1 is highly expressed in bladder cancer and is associated with migration and invasion.
Article in Oncology letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 12 citations in OpenAlex.
- Targeting RRBP1 reverses immune evasion and enhances immunotherapy efficacy via the CXCL10-CXCR3 axis in bladder cancer.Journal for immunotherapy of cancer · 2026Article
- Ribosome-binding protein 1: A multidimensional regulator of cancer progression and a novel target for precision therapy (Review).Oncology letters · 2026Review
- Stabilization of RRBP1 mRNA via an mCellular and molecular life sciences : CMLS · 2024Article
- Article
- Endoplasmic reticulum stress increases exosome biogenesis and packaging relevant to sperm maturation in response to oxidative stress in obese mice.Reproductive biology and endocrinology : RB&E · 2022Article
- Article
- USP35 mitigates endoplasmic reticulum stress-induced apoptosis by stabilizing RRBP1 in non-small cell lung cancer.Molecular oncology · 2022Article
- C-C Chemokine Receptor 7 in Cancer.Cells · 2022Review
- Hypomethylated RRBP1 Potentiates Tumor Malignancy and Chemoresistance in Upper Tract Urothelial Carcinoma.International journal of molecular sciences · 2021Article
- Ghrelin after chemotherapy as a prognostic predictor of progression-free survival in patients with muscle-invasive bladder cancer.Translational andrology and urology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ribosome-binding protein 1 (RRBP1) is a marker for colorectal, lung, esophageal and prostate cancer. However, the association between RRBP1 and bladder cancer is not completely understood. The present study aimed to evaluate the expression and function of RRBP1 in bladder cancer. The association between RRBP1 expression and clinicopathological characteristics, as well as the prognosis of bladder cancer was analyzed. RRBP1 expression was further analyzed in bladder cancer cell lines via reverse transcription-quantitative PCR and western blotting. RRBP1 knockdown was established using short hairpin RNAs to investigate the function of RRBP1 in T24 cells. Compared with healthy bladder tissue, RRBP1 expression levels were significantly upregulated in bladder cancer tissue. High RRBP1 expression was associated with tumor stage, lymph node metastasis and shorter overall survival time. RRBP1 protein was highly expressed in bladder cancer cell lines compared with normal SV-HUC-1 cells. Compared with the control group, RRBP1 knockdown inhibited T24 migration and invasion by downregulating the expression of C-C chemokine receptor type 7 (CCR7) protein. In conclusion, the present study indicated that RRBP1 was associated with bladder cancer migration, invasion and prognosis, and CCR7 might serve a role in the process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.